167 related articles for article (PubMed ID: 22039929)
21. Developing multidrug-resistant cells and exploring correlation between BCRP/ABCG2 over-expression and DNA methyltransferase.
Ji N; Yuan J; Liu J; Tian S
Acta Biochim Biophys Sin (Shanghai); 2010 Dec; 42(12):854-62. PubMed ID: 21106767
[TBL] [Abstract][Full Text] [Related]
22. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
[TBL] [Abstract][Full Text] [Related]
23. Dietary polyacetylenes of the falcarinol type are inhibitors of breast cancer resistance protein (BCRP/ABCG2).
Tan KW; Killeen DP; Li Y; Paxton JW; Birch NP; Scheepens A
Eur J Pharmacol; 2014 Jan; 723():346-52. PubMed ID: 24269959
[TBL] [Abstract][Full Text] [Related]
24. The role of breast cancer resistance protein in acute lymphoblastic leukemia.
Plasschaert SL; van der Kolk DM; de Bont ES; Kamps WA; Morisaki K; Bates SE; Scheffer GL; Scheper RJ; Vellenga E; de Vries EG
Clin Cancer Res; 2003 Nov; 9(14):5171-7. PubMed ID: 14613996
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and biological investigation of 2,4-substituted quinazolines as highly potent inhibitors of breast cancer resistance protein (ABCG2).
Krapf MK; Gallus J; Wiese M
Eur J Med Chem; 2017 Oct; 139():587-611. PubMed ID: 28841513
[TBL] [Abstract][Full Text] [Related]
26. C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.
Bram EE; Ifergan I; Grimberg M; Lemke K; Skladanowski A; Assaraf YG
Biochem Pharmacol; 2007 Jun; 74(1):41-53. PubMed ID: 17481587
[TBL] [Abstract][Full Text] [Related]
27. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
Pick A; Wiese M
ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
[TBL] [Abstract][Full Text] [Related]
28. ABCG2: recent discovery of potent and highly selective inhibitors.
Lecerf-Schmidt F; Peres B; Valdameri G; Gauthier C; Winter E; Payen L; Di Pietro A; Boumendjel A
Future Med Chem; 2013 Jun; 5(9):1037-45. PubMed ID: 23734686
[TBL] [Abstract][Full Text] [Related]
29. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
30. Cyclosporin A, tacrolimus and sirolimus are potent inhibitors of the human breast cancer resistance protein (ABCG2) and reverse resistance to mitoxantrone and topotecan.
Gupta A; Dai Y; Vethanayagam RR; Hebert MF; Thummel KE; Unadkat JD; Ross DD; Mao Q
Cancer Chemother Pharmacol; 2006 Sep; 58(3):374-83. PubMed ID: 16404634
[TBL] [Abstract][Full Text] [Related]
31. Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.
Boumendjel A; Macalou S; Ahmed-Belkacem A; Blanc M; Di Pietro A
Bioorg Med Chem; 2007 Apr; 15(8):2892-7. PubMed ID: 17317193
[TBL] [Abstract][Full Text] [Related]
32. The linker region of breast cancer resistance protein ABCG2 is critical for coupling of ATP-dependent drug transport.
Macalou S; Robey RW; Jabor Gozzi G; Shukla S; Grosjean I; Hegedus T; Ambudkar SV; Bates SE; Di Pietro A
Cell Mol Life Sci; 2016 May; 73(9):1927-37. PubMed ID: 26708291
[TBL] [Abstract][Full Text] [Related]
33. Dinaciclib, a cyclin-dependent kinase inhibitor, is a substrate of human ABCB1 and ABCG2 and an inhibitor of human ABCC1 in vitro.
Cihalova D; Ceckova M; Kucera R; Klimes J; Staud F
Biochem Pharmacol; 2015 Dec; 98(3):465-72. PubMed ID: 26300056
[TBL] [Abstract][Full Text] [Related]
34. Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Shi Z; Tiwari AK; Shukla S; Robey RW; Singh S; Kim IW; Bates SE; Peng X; Abraham I; Ambudkar SV; Talele TT; Fu LW; Chen ZS
Cancer Res; 2011 Apr; 71(8):3029-41. PubMed ID: 21402712
[TBL] [Abstract][Full Text] [Related]
35. Ulixertinib (BVD-523) antagonizes ABCB1- and ABCG2-mediated chemotherapeutic drug resistance.
Ji N; Yang Y; Lei ZN; Cai CY; Wang JQ; Gupta P; Xian X; Yang DH; Kong D; Chen ZS
Biochem Pharmacol; 2018 Dec; 158():274-285. PubMed ID: 30431011
[TBL] [Abstract][Full Text] [Related]
36. Resistance to mitoxantrone in multidrug-resistant MCF7 breast cancer cells: evaluation of mitoxantrone transport and the role of multidrug resistance protein family proteins.
Diah SK; Smitherman PK; Aldridge J; Volk EL; Schneider E; Townsend AJ; Morrow CS
Cancer Res; 2001 Jul; 61(14):5461-7. PubMed ID: 11454692
[TBL] [Abstract][Full Text] [Related]
37. Effects of dihydropyridines and pyridines on multidrug resistance mediated by breast cancer resistance protein: in vitro and in vivo studies.
Zhou XF; Yang X; Wang Q; Coburn RA; Morris ME
Drug Metab Dispos; 2005 Aug; 33(8):1220-8. PubMed ID: 15908473
[TBL] [Abstract][Full Text] [Related]
38. Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.
Valdameri G; Genoux-Bastide E; Peres B; Gauthier C; Guitton J; Terreux R; Winnischofer SM; Rocha ME; Boumendjel A; Di Pietro A
J Med Chem; 2012 Jan; 55(2):966-70. PubMed ID: 22165858
[TBL] [Abstract][Full Text] [Related]
39. Pelitinib (EKB-569) targets the up-regulation of ABCB1 and ABCG2 induced by hyperthermia to eradicate lung cancer.
To KK; Poon DC; Wei Y; Wang F; Lin G; Fu L
Br J Pharmacol; 2015 Aug; 172(16):4089-106. PubMed ID: 25988710
[TBL] [Abstract][Full Text] [Related]
40. A novel two mode-acting inhibitor of ABCG2-mediated multidrug transport and resistance in cancer chemotherapy.
Peng H; Dong Z; Qi J; Yang Y; Liu Y; Li Z; Xu J; Zhang JT
PLoS One; 2009 May; 4(5):e5676. PubMed ID: 19479068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]